MeiraGTx Holdings has today announced a multi-million euro expansion in its Shannon facility. The vertically integrated, clinical-stage gene therapy company has selected Shannon as the site of its second current good manufacturing practices and cGMP plasmid production facility.
These facilities will be designed for the manufacture of commercial-grade gene therapies in a fully integrated manner supported by MeiraGTx’s global quality assurance organisation. The company expects the Irish facilities, to provide additional flexibility as well as further large-scale capacity for clinical and commercial supply of its gene therapy product candidates from pre-clinical stages through clinical trials and potential commercialisation. This project is supported by the Irish Government through IDA Ireland.
The plasmid production facility is expected to be operational by year-end 2020, while the viral vector manufacturing facility is expected to be operational by year-end 2021.
Speaking this week, Executive Director of IDA Ireland, Mary Buckley said, "Today’s announcement by MeiraGTx is closely aligned with IDA Ireland’s strategy for the Life Sciences sector, and indeed in winning jobs and investment in regional locations. This investment is an emergent area within Biopharma, and strongly endorses the Midwest and Ireland’s reputation as a key location for the next generation of biopharmaceutical manufacture."